Cagrisema Side Effects: What the REDEFINE Program Has Shown
For the broader cluster context, see the semaglutide side effects and safety hub.
Author: HealthRX.com Editorial Team Evidence checked by: the HealthRX.com Editorial Team Last clinical review: May 2026
Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.
CagriSema combines cagrilintide with semaglutide. Its side-effect evidence needs to come from trials of that combination, rather than a generic account of semaglutide alone. The published REDEFINE 1 trial supplies a direct answer for adults with overweight or obesity without diabetes.
What REDEFINE 1 Studied
REDEFINE 1 followed participants for 68 weeks and compared cagrilintide 2.4 mg plus semaglutide 2.4 mg with semaglutide alone, cagrilintide alone and placebo. All groups also received lifestyle interventions. These are specified trial treatments, not a survey of compounded semaglutide programs.
The Reported Gastrointestinal Effects
Gastrointestinal adverse events affected 79.6% of the combination group and 39.9% of the placebo group. The publication describes nausea, vomiting, diarrhea, constipation and abdominal pain, with events mainly transient and mild to moderate. Those percentages count people with gastrointestinal events overall; they are not nausea rates.
The comparison is within this trial and population. It does not establish what will happen to a particular person, or the same event rate for a different preparation. A useful discussion of tolerability identifies the treatment arm, dose, population and follow-up period before comparing percentages.
Why Semaglutide Alone Is a Different Question
STEP 1 studied once-weekly semaglutide 2.4 mg with lifestyle intervention. It did not study the two-drug CagriSema regimen. It also did not compare commercially prescribed compounded preparations against branded semaglutide.
The molecule is relevant background, but trial results belong to the actual product and regimen studied. Adding a second active ingredient cannot be treated as merely another name for the first. Likewise, the trial record does not demonstrate matching side-effect profiles across compounded programs.
Reading the Results Without Turning Them Into Promises
Weight change and adverse events are separate outcomes. A headline weight-loss result is not a forecast for someone taking semaglutide alone, and a gastrointestinal-event percentage cannot tell an individual how severe or long-lasting their symptoms will be. Ask which published trial supports the specific comparison being made.
When to Actually Pick Up the Phone
Most GI side effects don't require a call. But patients tend to underestimate when they should reach out, not overestimate. The threshold should be lower than you think.
Call your prescriber for:
- Vomiting lasting more than one day
- Severe upper abdominal pain, especially if it radiates to the back
- Signs of dehydration (dark urine, dizziness, rapid heart rate)
- Jaundice
- Persistent severe headache or vision changes
Most garden-variety nausea, mild constipation, or reduced appetite can be managed with a dose hold or symptomatic care. But the items on that list above need a clinical conversation, not a wait-and-see approach.
Related Topics in This Cluster
- Is Wegovy Safe? Reviewing the Trial Data
- Can Wegovy Make You Tired? Fatigue on GLP-1 Therapy
- Does Wegovy Cause Constipation?
Adjacent Reading
For preparation-specific background, see the semaglutide side-effect guide and compounded semaglutide guide.
Frequently Asked Questions
Are the side effects of compounded semaglutide different from Wegovy or Ozempic?
The trials cited here do not establish matching rates across compounded programs. REDEFINE 1 studied cagrilintide plus semaglutide and specified single-drug comparators; it did not compare compounded products. Compounded preparations are not FDA-approved and have not been independently studied in the same way.
When should a side effect trigger a call to the prescriber?
Severe abdominal pain, persistent vomiting, signs of dehydration, jaundice, or vision changes are reasons to contact the prescribing clinician promptly. Most GI side effects are dose-related and improve with adjustment.
Do side effects predict effectiveness?
Side effects are not a treatment target. The pooled STEP analysis found weight loss with semaglutide 2.4 mg was largely independent of gastrointestinal events; that analysis does not establish the same relationship for every combination regimen.
Is cagrisema the same thing as compounded semaglutide?
No. CagriSema combines cagrilintide and semaglutide. Semaglutide alone is a different regimen; a compounded semaglutide prescription should not be treated as the combination studied in REDEFINE 1.
Should I expect the REDEFINE side effect data to reflect my experience on compounded semaglutide?
No. REDEFINE 1 evaluated specified combination and comparator arms, not compounded semaglutide programs. Its results describe the trial population and treatments rather than your predicted response to a different preparation.
Compliance and Authorship
It is intended as patient education and does not replace consultation with a licensed clinician.
Author: HealthRX.com Editorial Team Evidence checked by: the HealthRX.com Editorial Team Last clinical review: May 2026
Compounded semaglutide is not FDA-approved. Not FDA-approved. HealthRX.com is not a medical practice. Medications referenced in this article are dispensed by licensed pharmacies through independent clinician evaluations. Individual results vary and depend on prescribed protocol, lifestyle factors, and clinical context.